Evidence mapPaperPMID 37561017Full record

ArticleeLife2023

Iron gets in the way.

Kuldeep Singh, Rajeev Malhotra

Abstract readEditorialComment
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Kuldeep SinghDivision of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States.ORCID 0000-0001-7187-4782
Rajeev MalhotraDivision of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States.ORCID 0000-0003-0120-4630

Funding

The Role of Arylsulfatase in Vascular CalcificationR01HL162928 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$629k
NHLBI NIH HHS R01 HL159514NHLBI NIH HHS R01 HL162928
6 · The paper itself

Abstract

Accumulation of iron with age may inhibit the benefits of hormone replacement therapy on cardiovascular disease in late postmenopause.

Indexed as

Cardiovascular DiseasesEstrogen Replacement TherapyFemaleHumansIronPostmenopauseIronatherosclerosiscell biologyestrogen receptor αhormone replacement therapyiron metabolismmousepostmenopause

Identifiers

PMID37561017
PMCPMC10414964

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.